New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 1, 2013
08:06 EDTAMRNAmarin announces notification of additional U.S. patent allowance
Amarin Corporation announced that the United States Patent and Trademark Office, or USPTO, has published notification of a Notice of Allowance for Amarin's U.S. Patent Application Serial Number 13/272,520 titled "Compositions and Methods for Lowering Triglycerides." This application includes claims intended to protect the proposed Vascepa indication based on Amarin's Phase 3 ANCHOR clinical trial results. Amarin is on track to file a Supplemental New Drug Application for the Vascepa ANCHOR indication with the FDA by the end of February, and expects an FDA action date on the application before the end of 2013. A Notice of Allowance is issued after the USPTO makes a determination that a patent can be granted from an application. The issued patent would have a term that expires no earlier than in 2030. Amarin plans to list this patent in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book, after issuance of the patent and approval of Vascepa in the ANCHOR indication. The claims in this allowed application cover a method of use relating to Vascepa's ANCHOR indication. Specifically, the allowed independent claims covers use of about 4 grams per day of highly pure icosapent ethyl, or EPA, including Vascepa, to lower triglycerides and LDL-C.
News For AMRN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 19, 2014
15:00 EDTAMRNStonepine Capital reports 5.2% passive stake in Amarin
November 17, 2014
09:06 EDTAMRNAmarin reports new data from MARINE, ANCHOR phase 3 studies
Amarin announced the presentation of new data and related analyses from the MARINE and ANCHOR phase 3 studies. The data show that use of Vascepa capsules significantly reduced remnant-like particle cholesterol, or RLP-C, levels -- a cardiovascular risk factor -- including significant placebo-adjusted reductions in RLP-C in studied patient populations with triglyceride, or TG, levels greater than or equal to 200 mg/dL and greater than or equal to 500 mg/dL, including patients that received statin therapy. The data were presented today by Dr. Christie M. Ballantyne as part of a moderated poster session at the American Heart Association Scientific Sessions in Chicago. Remnant-like particle cholesterol is an important emerging risk factor for cardiovascular disease and represents the cholesterol content of a subset of triglyceride-rich lipoproteins, or TRL, called remnants. In the fasting state this subset of TRLs is comprised of very low-density lipoproteins, or VLDL, and intermediate-density lipoproteins, or IDL, and in the non-fasting state includes these two types of lipoproteins together with chylomicron remnants.Elevated plasma TG levels are a marker of elevated remnant cholesterol and are associated with increased risk for cardiovascular disease.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use